Drugs / Betamethasone Microsphere
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01512901 | — | occlusion of tributary of retinal vein | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT01411254 | — | diabetic macular edema | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betamethasone Microsphere | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01512901 ↗ |
| Known as | DE-102 | “Betamethasone Microsphere (DE-102） Low Dose” NCT01411254 ↗1“Betamethasone Microsphere (DE-102） Low Dose” NCT01512901 ↗ |